Amylyx Pharmaceuticals is a clinical-stage company; its lead candidate, avexitide, is not yet approved for treating post-bariatric hypoglycemia, a disabling blood-sugar disorder that can follow weight-loss surgery.
Amylyx's case rests on avexitide, a once-daily injected GLP-1 receptor antagonist for post-bariatric hypoglycemia, sometimes dangerous low blood sugar after gastric bypass for which no drug is approved. In the Phase 3 LUCIDITY trial of 78 adults it cut Level 2 and 3 hypoglycemic events by 55% versus placebo, meeting the FDA-agreed primary endpoint and all secondary endpoints. Amylyx plans an NDA by the end of 2026 and a 2027 launch if approved, funded by $250.8 million in cash and a $471.7 million August offering.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Amylyx submits the NDA by year-end
Does Amylyx submit a complete NDA on time, and does FDA accept it for review?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Amylyx plans to submit an NDA for avexitide in post-bariatric hypoglycemia by year-end after the Phase 3 LUCIDITY trial cut serious low-blood-sugar events by 55%; an August offering raised $471.7 million net to fund a 2027 launch
Clean Phase 3 win in post-bariatric hypoglycemia positions avexitide for NDA filing; approval converts a no-revenue rebuilding story into a commercial franchise
Avexitide's pivotal Phase 3 readout in post-bariatric hypoglycemia is the single event that determines whether Amylyx's cash-rich rebuild produces an approved drug or a preclinical holding company
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neurology and pain, Obesity, diabetes and heart disease, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
13 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.